You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Bristol Myers Squibb Company Profile


✉ Email this page to a colleague

« Back to Dashboard


Summary for Bristol Myers Squibb
International Patents:596
US Patents:13
Tradenames:60
Ingredients:55
NDAs:70

Drugs and US Patents for Bristol Myers Squibb

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb VESPRIN triflupromazine hydrochloride TABLET;ORAL 011123-003 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Bristol Myers Squibb PRINCIPEN ampicillin/ampicillin trihydrate CAPSULE;ORAL 061392-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Bristol Myers Squibb REVLIMID lenalidomide CAPSULE;ORAL 021880-003 Jun 29, 2006 AB RX Yes No 8,741,929 ⤷  Try a Trial ⤷  Try a Trial
Bristol Myers Squibb IDHIFA enasidenib mesylate TABLET;ORAL 209606-002 Aug 1, 2017 RX Yes Yes 10,093,654 ⤷  Try a Trial Y Y ⤷  Try a Trial
Bristol Myers Squibb PRAVIGARD PAC (COPACKAGED) aspirin; pravastatin sodium TABLET;ORAL 021387-002 Jun 24, 2003 DISCN No No ⤷  Try a Trial ⤷  Try a Trial
Bristol Myers Squibb REVLIMID lenalidomide CAPSULE;ORAL 021880-005 Dec 21, 2011 AB RX Yes No ⤷  Try a Trial ⤷  Try a Trial
Bristol Myers Squibb SPRYCEL dasatinib TABLET;ORAL 021986-001 Jun 28, 2006 RX Yes No ⤷  Try a Trial ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Bristol Myers Squibb

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Bristol Myers Squibb REVLIMID lenalidomide CAPSULE;ORAL 021880-003 Jun 29, 2006 6,561,976 ⤷  Try a Trial
Bristol Myers Squibb VIDEX didanosine TABLET, CHEWABLE;ORAL 020154-005 Oct 9, 1991 5,616,566*PED ⤷  Try a Trial
Bristol Myers Squibb REVLIMID lenalidomide CAPSULE;ORAL 021880-004 Jun 29, 2006 9,155,730 ⤷  Try a Trial
Bristol Myers Squibb REVLIMID lenalidomide CAPSULE;ORAL 021880-003 Jun 29, 2006 8,589,188 ⤷  Try a Trial
Bristol Myers Squibb REVLIMID lenalidomide CAPSULE;ORAL 021880-001 Dec 27, 2005 7,468,363 ⤷  Try a Trial
Bristol Myers Squibb MONOPRIL fosinopril sodium TABLET;ORAL 019915-003 May 16, 1991 4,384,123 ⤷  Try a Trial
Bristol Myers Squibb MONOPRIL-HCT fosinopril sodium; hydrochlorothiazide TABLET;ORAL 020286-001 Nov 30, 1994 5,006,344*PED ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration
Paragraph IV (Patent) Challenges for BRISTOL MYERS SQUIBB drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Nasal Spray 4 mg/spray ➤ Subscribe 2016-07-15
➤ Subscribe Tablets 2.5 mg and 5 mg ➤ Subscribe 2016-12-28
➤ Subscribe Tablets 20 mg, 50 mg, 70 mg and 100 mg ➤ Subscribe 2010-06-28
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-17
➤ Subscribe Delayed-release Capsules 200 mg, 250 mg and 400 mg ➤ Subscribe 2004-06-01
➤ Subscribe Capsules 5 mg, 10 mg and 15 mg ➤ Subscribe 2010-08-30
➤ Subscribe Capsules 300 mg ➤ Subscribe 2009-07-20
➤ Subscribe Capsules 200 mg ➤ Subscribe 2010-02-16
➤ Subscribe Capsules 50 mg, 100 mg and 200 mg ➤ Subscribe 2016-11-03
➤ Subscribe Tablets 0.5 mg and 1 mg ➤ Subscribe 2010-06-14
➤ Subscribe Tablets 30 mg ➤ Subscribe 2005-06-01
➤ Subscribe Tablets 80 mg and 140 mg ➤ Subscribe 2011-06-16
➤ Subscribe Capsules 25 mg ➤ Subscribe 2010-07-12
➤ Subscribe Capsules 2.5 mg and 20 mg ➤ Subscribe 2016-07-12
➤ Subscribe Capsules 100 mg and 150 mg ➤ Subscribe 2010-03-19
➤ Subscribe Tablets 600 mg ➤ Subscribe 2009-04-09

Supplementary Protection Certificates for Bristol Myers Squibb Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0398460 SPC/GB04/032 United Kingdom ⤷  Try a Trial PRODUCT NAME: ESTRADIOL, OPTIONALLY IN THE FORM OF A HYDRATE, TOGETHER WITH DROSPIRENONE; REGISTERED: NL RVG 27505 20021211; UK PL 00053/0341 20040310
1380301 CA 2009 00017 Denmark ⤷  Try a Trial PRODUCT NAME: ETHINYLESTRADIOL (SOM BETADEXCLATHRAT) OG DROSPIRENON; NAT. REG. NO/DATE: 42417 (DK) 20080619; FIRST REG. NO/DATE: NL 33842 20070629
2105135 C20150005 00140 Estonia ⤷  Try a Trial PRODUCT NAME: POMALIDOMIID;REG NO/DATE: EU/1/13/850 08.08.2013
1304992 C01304992/01 Switzerland ⤷  Try a Trial PRODUCT NAME: CLINDAMYCINI PHOSPHAS ET TRETINOINUM; REGISTRATION NO/DATE: SWISSMEDIC 62513 28.03.2014
1427415 C 2011 008 Romania ⤷  Try a Trial PRODUCT NAME: APIXABANSI SARURI ACCEPTABILE FARMACEUTIC ALE ACESTUIA; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/691/001, RO EU/1/11/691/002, RO EU/1/11/691/003, RO EU/1/11/691/004, RO EU/1/11/691/005; DATE OF NATIONAL AUTHORISATION: 20110518; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/691/001, EU/1/11/691/002, EU/1/11/691/003, EU/1/11/691/004, EU/1/11/691/005; DATE OF FIRST AUTHORISATION IN EEA: 20110518
2487163 60/2016 Austria ⤷  Try a Trial PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON UND ATAZANAVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON, INSBESONDERE ATAZANAVIR-SULFAT; REGISTRATION NO/DATE: EU/1/15/1025 (MITTEILUNG) 20150715
0582455 SPC/GB08/022 United Kingdom ⤷  Try a Trial PRODUCT NAME: A COMBINATION OF EFAVIRENZ, EMTRICITABINE OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF, AND TENOFOVIR OR A PHARMACEUTICALLY ACCEPTABLE PRODRUG, SALT OR ESTER THEREOF, PARTICULARLY TENOFOVIR DISOPROXIL, ESPECIALLY TENOFOVIR DISOPROXIL FUMARATE; REGISTERED: UK EU/1/07/430/001 20071213
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.